Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Biotechnology

Healthcare
$0.46 -0.01%

-$0.00 today

Market cap
$57.32M
Beta
0.96
P/E (TTM)
-2.5
EPS (TTM)
-$0.52
52W Low $1.00High $3.06

Volume 2.23M

Average 1.99M

Returns on capital

Milestone Pharmaceuticals Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-151.0%

avg -107.3%

ROIC

-62.0%

avg -53.7%

ROA

-55.5%

avg -48.6%

Analysis

ROA is currently the strongest return metric at -55.5% versus its period average of -48.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Joseph G. Oliveto

Chief Executive Officer, President & DirectorUSD 931.38K58——

David Bharucha FACC

Chief Medical OfficerUSD 664.42K64——

Amit Hasija

Chief Financial Officer & Executive Vice President of Corporate DevelopmentUSD 631.86K53204.00K0.24%

Guy Rousseau

SVP of Regulatory Affairs and Quality Management————

Philippe Douville

Founder, Strategic Advisor & Member of Scientific Advisory Board—640<0.01%

Philip T. Sager FACC FAHA FHRS

Chief Medical Advisor & Member of the Scientific Advisory Board—70——

Jeff Moore

Vice President of Sales————

Jeff Nelson

Chief Operating Officer—45——

Roshan Girglani

Vice President of Marketing————

David Sandoval

General Counsel & Chief Compliance Officer—48——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 2, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

13

$1.18M

Net Transaction Value

−$1.18M

Net selling

Most Active

Oliveto Joseph

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Apr 16, 26

Oliveto Joseph

Direct

Sell$82.5K
Jan 26, 26

Bharucha David

Direct

Sell$23.6K
Jan 26, 26

Muller Lorenz

Direct

Sell$21.6K
Jan 26, 26

Hasija Amit

Direct

Sell$23.6K
Jan 26, 26

Oliveto Joseph

Direct

Sell$66.6K
Jan 26, 26

Nelson Jeffrey Edward

Direct

Sell$23.6K
Jan 8, 26

Oliveto Joseph

Direct

Sell$96.8K
Jan 7, 26

Oliveto Joseph

Direct

Sell$1.1K
Dec 15, 25

Nelson Jeffrey Edward

Direct

Sell$134.6K
Dec 15, 25

Bharucha David

Direct

Sell$134.6K

1–10 of 13

Summary

Insiders reported 0 buys worth $0.00 and 13 sells worth $1.18M over the last 12 months. That adds up to net selling of $1.18M. Oliveto Joseph was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-32.4%
+149.2% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at -32.4% over three years. Forward estimates point to Revenue at +149.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Milestone Pharmaceuticals Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about MIST's management, answered from reported figures.

Who manages MIST?

Milestone Pharmaceuticals Inc. (MIST) lists 10 active executives. The top listed executive is David Bharucha FACC, Chief Medical Officer.

Are MIST insiders buying or selling?

Recent insider activity shows net buying of $27.55M.